#USA #Boston #Morphic Medical #RESET #Terri Cooper

Morphic Medical Expands Leadership for Enhanced Growth

Morphic Medical, the pioneering company behind the world's first medical device engineered to address the root cause of Type 2 diabetes, has made significant strides forward with new appointments in its Board of Directors. Announced on August 6, 2026, the company has appointed Dr. Terri Cooper as Chair of the Board and Craig Richardson as a new non-executive board member. These strategic moves come at a pivotal time for Morphic Medical, following the successful CE mark approval of RESET® and ongoing commercial expansion in Europe. As the company prepares for broader access to international markets, these appointments signal an commitment to strategic growth and enhanced patient care.

Leadership at the Helm

Dr. Terri Cooper brings a wealth of experience in the healthcare sector. As Chair, she will collaborate closely with the management team to support the company’s strategic initiatives, governance, and long-term value creation. Her extensive background in establishing successful health enterprises positions her perfectly to guide Morphic Medical through this exciting phase of growth.

Dr. Cooper expressed her enthusiasm, stating, "Morphic Medical has developed innovative and differentiated technology with the potential to transform obesity and metabolic disease management. After achieving significant clinical, regulatory, and commercial milestones, the company is well-positioned for its next growth phase. I look forward to working with the Board and management team to build a leading global organization in metabolic health."

Joining Dr. Cooper is Craig Richardson, whose deep expertise in health economics and market access will be invaluable as Morphic Medical continues to forge partnerships with payers, providers, and policymakers. His focus on demonstrating clinical and economic value is expected to play a crucial role in expanding patient access to RESET® in key markets.

"The burden of obesity and Type 2 diabetes is escalating worldwide, making it vital for innovative therapies to deliver strong clinical outcomes and economic value," Richardson noted. "RESET® has the potential to offer significant benefits for patients while reducing long-term healthcare costs. I am excited to join the Board and support Morphic Medical in generating the necessary evidence and partnerships for maximizing patient access."

Acknowledging Previous Leadership

Mike Gutteridge, CEO of Morphic Medical, expressed gratitude towards Mark Lerdal for his leadership and contributions during his tenure as Board Chair. With the future in focus, Gutteridge welcomed Terri and Craig, emphasizing the strategic leadership they will bring to enhance the company's future endeavors. He stated, "Terri's strategic leadership and vast experience in building successful health companies make her the right person to lead Morphic Medical’s next growth phase. Craig’s knowledge in health economics will prove critical as we continue showing the clinical and economic value of RESET® across global health systems. Together, they significantly strengthen our Board and reinforce our commitment to improving the lives of patients with obesity and Type 2 diabetes."

Commitment to Patient Outcomes

The recent appointments reflect Morphic Medical’s ongoing commitment to assemble a premier Board of Directors equipped with the necessary expertise to support its business strategy, international expansion, and long-term mission of enhancing health outcomes for patients battling obesity and Type 2 diabetes.

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical has developed RESET, a non-surgical endoscopic therapy that offers an alternative treatment for severe obesity and related cardiometabolic risk factors, including Type 2 diabetes and dyslipidemia. RESET is approved for sale in the EU and the UK, while its usage in the U.S. is currently limited to research. For more information, visit morphicmedical.com or follow the company on Twitter and LinkedIn.